Key Segmentation
By Test Type
-
NS1 Antigen Test
-
IgM Antibody Test
-
IgG Antibody Test
-
RT-PCR Test
By Technology
-
ELISA
-
Rapid Diagnostic Tests (RDTs)
-
PCR
-
Others
By Product Type
-
Test Kits
-
Instruments
-
Reagents & Consumables
-
Others
By End-User
-
Hospitals
-
Diagnostic Laboratories
-
Public Health Laboratories
-
Research Institutes
By Sample Type
-
Blood
-
Serum
-
Plasma
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: Asia Pacific dominated the market due to advanced healthcare infrastructure and strong diagnostic adoption, and also it is the fastest-growing region, driven by high disease burden, expanding healthcare access, and increasing testing volumes.
Ans: NS1 Antigen Test dominated with a 34.25% share in 2025, while RT-PCR Test accounted for 6.74% and remains widely used for early detection across healthcare settings.
Ans: Growth is driven by rising dengue prevalence, increasing demand for early and accurate diagnosis, expansion of diagnostic infrastructure, adoption of rapid and molecular testing technologies, and government-led disease surveillance programs.
Ans: The market is valued at USD 594.76 Million in 2025 and is projected to reach USD 971.11 Million by 2035.
Ans: The Dengue Testing Market is projected to grow at a CAGR of 5.08% during 2026–2035.